Symbols / MTNB Stock $0.56 +1.84% Matinas BioPharma Holdings, Inc.
MTNB (Stock) Chart
About
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Fundamentals
Scroll to Statements| Market Cap | 3.59M | Enterprise Value | 943.75K | Income | -10.96M | Sales | — | Book/sh | 0.75 | Cash/sh | 0.62 |
| Dividend Yield | — | Payout | 0.00% | Employees | 2 | IPO | — | P/E | — | Forward P/E | -0.19 |
| PEG | — | P/S | — | P/B | 0.74 | P/C | — | EV/EBITDA | -0.14 | EV/Sales | — |
| Quick Ratio | 2.73 | Current Ratio | 2.79 | Debt/Eq | 28.03 | LT Debt/Eq | — | EPS (ttm) | -2.00 | EPS next Y | -3.00 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2025-08-13 | ROA | -43.83% | ROE | -166.59% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 6.41M | Shs Float | 5.23M | Short Float | 0.14% |
| Short Ratio | 0.15 | Short Interest | — | 52W High | 3.09 | 52W Low | 0.48 | Beta | 1.40 | Avg Volume | 27.97K |
| Volume | 18.78K | Target Price | — | Recom | None | Prev Close | $0.55 | Price | $0.56 | Change | 1.84% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.56
Latest analyst target
3. DCF / Fair value
$-9.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.56
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-10-31 | down | Maxim Group | Buy → Hold | — |
| 2023-01-31 | reit | HC Wainwright & Co. | — → Buy | $3 |
| 2020-08-13 | main | Aegis Capital | — → Buy | $4 |
| 2020-01-27 | init | Piper Sandler | — → Overweight | $3 |
| 2020-01-24 | init | SunTrust Robinson Humphrey | — → Buy | $3 |
| 2019-06-26 | init | HC Wainwright & Co. | — → Buy | $4 |
| 2019-05-17 | init | BTIG | — → Buy | $5 |
| 2019-02-11 | init | Roth Capital | — → Buy | — |
| 2018-11-13 | main | Maxim Group | Buy → Buy | $5 |
| 2018-08-13 | main | Maxim Group | Buy → Buy | $2 |
| 2018-07-10 | main | Maxim Group | Buy → Buy | $3 |
- Matinas BioPharma has until May 2 to answer NYSE notice - Stock Titan Fri, 03 Apr 2026 07
- Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203 - Yahoo Finance ue, 23 Sep 2025 07
- Matinas BioPharma Holdings, Inc. Notifies NYSE American of Non-Compliance with Continued Listing Standards - Quiver Quantitative Fri, 03 Apr 2026 07
- Matinas BioPharma CEO Named Interim Chief Financial Officer - The Globe and Mail Sat, 24 Jan 2026 08
- Matinas BioPharma Faces NYSE American Listing Compliance Notice - TipRanks Fri, 03 Apr 2026 07
- symbol__ Stock Quote Price and Forecast - CNN Wed, 14 Feb 2024 19
- Matinas BioPharma (NYSE American: MTNB) faces NYSE non-compliance and cure deadline - Stock Titan Fri, 03 Apr 2026 07
- Matinas BioPharma Faces NYSE Compliance Issues - Intellectia AI Sat, 04 Apr 2026 07
- MTNB Stock Price and Chart — AMEX:MTNB - TradingView Sat, 29 Jul 2017 04
- Matinas Biopharma Holdings Stock Price Forecast. Should You Buy MTNB? - StockInvest.us Wed, 02 Dec 2020 05
- Matinas BioPharma Announces Agreement for the Acquisition - GlobeNewswire hu, 13 Feb 2025 08
- Matinas BioPharma stock falls on strategic options (MTNB:NYSE) - Seeking Alpha hu, 31 Oct 2024 07
- What is the current Price Target and Forecast for Matinas Biopharma (MTNB) - Zacks Investment Research ue, 30 Aug 2022 02
- MTNB Forecast — Price Prediction for 2026. Should I Buy MTNB? - Intellectia AI ue, 15 Apr 2025 16
- 4 Cheap Penny Stocks To Buy On Robinhood For Under $1 Right Now - Yahoo Finance Mon, 13 Sep 2021 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
1.10
-65.62%
|
3.19
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
1.10
-65.62%
|
3.19
|
| Operating Expense |
|
6.96
-65.48%
|
20.16
-18.90%
|
24.86
-10.50%
|
27.78
|
| Research And Development |
|
0.09
-99.26%
|
11.43
-21.09%
|
14.49
-13.13%
|
16.68
|
| Selling General And Administration |
|
6.88
-21.24%
|
8.73
-15.85%
|
10.37
-6.55%
|
11.10
|
| General And Administrative Expense |
|
6.88
-21.24%
|
8.73
-15.85%
|
10.37
-6.55%
|
11.10
|
| Other Gand A |
|
6.88
-21.24%
|
8.73
-15.85%
|
10.37
-6.55%
|
11.10
|
| Total Expenses |
|
6.96
-65.48%
|
20.16
-18.90%
|
24.86
-10.50%
|
27.78
|
| Operating Income |
|
-6.96
+65.48%
|
-20.16
+15.16%
|
-23.77
+3.35%
|
-24.59
|
| Total Operating Income As Reported |
|
-6.96
+71.70%
|
-24.59
-3.48%
|
-23.77
+3.35%
|
-24.59
|
| EBITDA |
|
-6.50
+66.11%
|
-19.19
+15.93%
|
-22.82
+3.66%
|
-23.69
|
| Normalized EBITDA |
|
-3.38
+77.10%
|
-14.76
+36.68%
|
-23.31
+14.25%
|
-27.18
|
| Reconciled Depreciation |
|
0.46
-53.09%
|
0.97
+3.29%
|
0.94
+4.79%
|
0.90
|
| EBIT |
|
-6.96
+65.48%
|
-20.16
+15.16%
|
-23.77
+3.35%
|
-24.59
|
| Total Unusual Items |
|
-3.12
+29.50%
|
-4.43
-1015.50%
|
0.48
-86.14%
|
3.49
|
| Total Unusual Items Excluding Goodwill |
|
-3.12
+29.50%
|
-4.43
-1015.50%
|
0.48
-86.14%
|
3.49
|
| Special Income Charges |
|
0.04
+100.84%
|
-4.43
-1015.50%
|
0.48
-86.14%
|
3.49
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
4.43
|
0.00
|
—
|
| Net Income |
|
-10.35
+57.34%
|
-24.25
-5.71%
|
-22.94
-9.26%
|
-21.00
|
| Pretax Income |
|
-10.35
+57.48%
|
-24.33
-6.05%
|
-22.94
-9.26%
|
-21.00
|
| Other Income Expense |
|
-3.38
+18.81%
|
-4.17
-605.95%
|
0.82
-77.07%
|
3.59
|
| Other Non Operating Income Expenses |
|
-0.26
-199.62%
|
0.26
-22.94%
|
0.34
+233.33%
|
0.10
|
| Gain On Sale Of Security |
|
-3.16
|
—
|
—
|
—
|
| Gain On Sale Of Business |
|
—
|
0.00
-100.00%
|
0.48
-86.14%
|
3.49
|
| Tax Provision |
|
0.00
+100.00%
|
-0.08
|
0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-0.01
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-10.35
+57.34%
|
-24.25
-5.71%
|
-22.94
-9.26%
|
-21.00
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.35
+57.34%
|
-24.25
-5.71%
|
-22.94
-9.26%
|
-21.00
|
| Net Income From Continuing And Discontinued Operation |
|
-10.35
+57.34%
|
-24.25
-5.71%
|
-22.94
-9.26%
|
-21.00
|
| Net Income Continuous Operations |
|
-10.35
+57.34%
|
-24.25
-5.71%
|
-22.94
-9.26%
|
-21.00
|
| Normalized Income |
|
-7.22
+63.59%
|
-19.83
+15.33%
|
-23.43
+4.34%
|
-24.49
|
| Net Income Common Stockholders |
|
-10.96
+54.79%
|
-24.25
-5.71%
|
-22.94
-9.26%
|
-21.00
|
| Otherunder Preferred Stock Dividend |
|
0.62
|
0.00
|
—
|
—
|
| Diluted EPS |
|
—
|
-4.98
+5.68%
|
-5.28
-5.60%
|
-5.00
|
| Basic EPS |
|
—
|
-4.98
+5.68%
|
-5.28
-5.60%
|
-5.00
|
| Basic Average Shares |
|
—
|
4.87
+11.98%
|
4.35
+0.21%
|
4.34
|
| Diluted Average Shares |
|
—
|
4.87
+11.98%
|
4.35
+0.21%
|
4.34
|
| Diluted NI Availto Com Stockholders |
|
-10.96
+54.79%
|
-24.25
-5.71%
|
-22.94
-9.26%
|
-21.00
|
| Gain On Sale Of PPE |
|
0.04
|
0.00
|
—
|
—
|
| Preferred Stock Dividends |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
25.10
|
| Current Assets |
|
15.54
|
| Cash Cash Equivalents And Short Term Investments |
|
13.76
|
| Cash And Cash Equivalents |
|
4.79
|
| Other Short Term Investments |
|
8.97
|
| Prepaid Assets |
|
—
|
| Restricted Cash |
|
0.05
|
| Other Current Assets |
|
1.74
|
| Total Non Current Assets |
|
9.56
|
| Net PPE |
|
5.01
|
| Gross PPE |
|
6.70
|
| Accumulated Depreciation |
|
-1.70
|
| Properties |
|
0.00
|
| Other Properties |
|
5.55
|
| Leases |
|
1.16
|
| Goodwill And Other Intangible Assets |
|
4.35
|
| Goodwill |
|
1.34
|
| Other Intangible Assets |
|
3.02
|
| Other Non Current Assets |
|
0.20
|
| Total Liabilities Net Minority Interest |
|
5.86
|
| Current Liabilities |
|
2.62
|
| Payables And Accrued Expenses |
|
1.96
|
| Payables |
|
0.51
|
| Accounts Payable |
|
0.51
|
| Current Accrued Expenses |
|
1.45
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.66
|
| Current Capital Lease Obligation |
|
0.66
|
| Current Deferred Liabilities |
|
0.00
|
| Current Deferred Revenue |
|
0.00
|
| Other Current Liabilities |
|
0.27
|
| Total Non Current Liabilities Net Minority Interest |
|
3.24
|
| Long Term Debt And Capital Lease Obligation |
|
2.90
|
| Long Term Capital Lease Obligation |
|
2.90
|
| Non Current Deferred Liabilities |
|
0.34
|
| Non Current Deferred Taxes Liabilities |
|
0.34
|
| Stockholders Equity |
|
19.25
|
| Common Stock Equity |
|
19.25
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
—
|
| Share Issued |
|
4.35
|
| Ordinary Shares Number |
|
4.35
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
195.04
|
| Retained Earnings |
|
-175.57
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.22
|
| Other Equity Adjustments |
|
-0.22
|
| Total Equity Gross Minority Interest |
|
19.25
|
| Total Capitalization |
|
19.25
|
| Working Capital |
|
12.92
|
| Invested Capital |
|
19.25
|
| Total Debt |
|
3.56
|
| Capital Lease Obligations |
|
3.56
|
| Net Tangible Assets |
|
14.89
|
| Tangible Book Value |
|
14.89
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.01
+55.86%
|
-15.88
-3.97%
|
-15.28
+20.24%
|
-19.16
|
| Cash Flow From Continuing Operating Activities |
|
-7.01
+55.86%
|
-15.88
-3.97%
|
-15.28
+20.24%
|
-19.16
|
| Net Income From Continuing Operations |
|
-10.35
+57.34%
|
-24.25
-5.71%
|
-22.94
-9.26%
|
-21.00
|
| Depreciation Amortization Depletion |
|
0.46
-53.09%
|
0.97
+3.29%
|
0.94
+4.79%
|
0.90
|
| Depreciation |
|
0.46
-53.09%
|
0.97
+3.29%
|
0.94
+4.79%
|
0.90
|
| Depreciation And Amortization |
|
0.46
-53.09%
|
0.97
+3.29%
|
0.94
+4.79%
|
0.90
|
| Other Non Cash Items |
|
—
|
-0.02
-115.89%
|
0.11
-78.69%
|
0.50
|
| Stock Based Compensation |
|
1.02
-67.98%
|
3.19
-35.43%
|
4.95
-5.36%
|
5.23
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
4.43
|
0.00
|
—
|
| Deferred Tax |
|
0.00
+100.00%
|
-0.08
|
0.00
|
—
|
| Deferred Income Tax |
|
0.00
+100.00%
|
-0.08
|
0.00
|
—
|
| Operating Gains Losses |
|
3.37
|
—
|
0.00
-50.00%
|
0.00
|
| Gain Loss On Investment Securities |
|
3.16
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
0.24
|
0.00
-100.00%
|
0.00
-50.00%
|
0.00
|
| Change In Working Capital |
|
-1.51
-1052.67%
|
-0.13
-107.86%
|
1.67
+134.81%
|
-4.79
|
| Change In Prepaid Assets |
|
0.67
+13.29%
|
0.59
-85.26%
|
3.98
+194.90%
|
-4.20
|
| Change In Payables And Accrued Expense |
|
-1.13
-1698.41%
|
-0.06
+96.41%
|
-1.75
-2336.11%
|
-0.07
|
| Change In Accrued Expense |
|
-1.35
-480.06%
|
0.36
+121.56%
|
-1.65
-763.05%
|
0.25
|
| Change In Payable |
|
0.22
+152.51%
|
-0.42
-306.80%
|
-0.10
+67.91%
|
-0.32
|
| Change In Account Payable |
|
0.22
+152.51%
|
-0.42
-306.80%
|
-0.10
+67.91%
|
-0.32
|
| Change In Other Current Liabilities |
|
-1.04
-59.08%
|
-0.66
-16.55%
|
-0.56
-8.08%
|
-0.52
|
| Investing Cash Flow |
|
0.34
-96.36%
|
9.21
-30.46%
|
13.24
+171.52%
|
4.88
|
| Cash Flow From Continuing Investing Activities |
|
0.34
-96.36%
|
9.21
-30.46%
|
13.24
+171.52%
|
4.88
|
| Net PPE Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.22
+75.56%
|
-0.89
|
| Purchase Of PPE |
|
—
|
0.00
+100.00%
|
-0.22
+75.56%
|
-0.89
|
| Capital Expenditure |
|
—
|
—
|
-0.22
+75.56%
|
-0.89
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
9.21
-31.59%
|
13.46
+133.32%
|
5.77
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-8.44
|
0.00
+100.00%
|
-9.48
|
| Sale Of Investment |
|
0.00
-100.00%
|
17.64
+31.09%
|
13.46
-11.74%
|
15.25
|
| Net Other Investing Changes |
|
0.34
|
—
|
—
|
—
|
| Financing Cash Flow |
|
3.39
-63.04%
|
9.17
+131157.14%
|
-0.01
-108.86%
|
0.08
|
| Cash Flow From Continuing Financing Activities |
|
3.39
-63.04%
|
9.17
+131157.14%
|
-0.01
-108.86%
|
0.08
|
| Net Issuance Payments Of Debt |
|
-0.01
-80.00%
|
-0.01
+28.57%
|
-0.01
+65.00%
|
-0.02
|
| Repayment Of Debt |
|
-0.01
-80.00%
|
-0.01
+28.57%
|
-0.01
+65.00%
|
-0.02
|
| Long Term Debt Payments |
|
-0.01
-80.00%
|
-0.01
+28.57%
|
-0.01
+65.00%
|
-0.02
|
| Net Long Term Debt Issuance |
|
-0.01
-80.00%
|
-0.01
+28.57%
|
-0.01
+65.00%
|
-0.02
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
9.18
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.13
|
0.00
|
0.00
-100.00%
|
0.10
|
| Net Other Financing Charges |
|
-0.03
|
—
|
—
|
—
|
| Changes In Cash |
|
-3.29
-231.56%
|
2.50
+222.22%
|
-2.04
+85.61%
|
-14.20
|
| Beginning Cash Position |
|
7.53
+49.57%
|
5.04
-28.86%
|
7.08
-66.73%
|
21.28
|
| End Cash Position |
|
4.25
-43.60%
|
7.53
+49.57%
|
5.04
-28.86%
|
7.08
|
| Free Cash Flow |
|
-7.01
+55.86%
|
-15.88
-2.51%
|
-15.50
+22.71%
|
-20.05
|
| Common Stock Issuance |
|
0.00
-100.00%
|
9.18
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
3.30
-64.05%
|
9.18
|
0.00
|
0.00
|
| Net Preferred Stock Issuance |
|
3.30
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
3.30
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-03 View
- 10-K2026-03-31 View
- 8-K2026-01-23 View
- 8-K2025-12-12 View
- 8-K2025-11-21 View
- 10-Q2025-11-10 View
- 8-K2025-08-18 View
- 10-Q2025-08-14 View
- 8-K2025-08-06 View
- 8-K2025-06-23 View
- 10-Q2025-05-15 View
- 42025-05-02 View
- 42025-05-02 View
- 42025-05-02 View
- 42025-05-02 View
- 42025-05-02 View
- 8-K2025-05-02 View
- 10-K2025-04-15 View
- 8-K2025-04-08 View
- 8-K2025-04-04 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|